Platelet-derived microparticles during and after acute coronary syndrome

Summary

As microparticles are shedded upon platelet activation, and may be used to assess platelet function, we measured plasma concentrations of platelet-derived microparticles (PMPs) during and after an acute coronary syndrome (ACS). Fifty-one patients with ACS were investigated at admission, within 24 hours (before coronary angiography), and six months later. Sixty-one sex- and age-matched healthy controls were investigated once. PMPs were defined as particles <1.0 μm in size, negative to phalloidin (labels cell-fragments), and positive to CD61. Exposure of phosphatidylserine (PS⁺), CD62P and CD142 were also measured. Plasma concentrations of PS⁺PMPs exposing CD61, CD62P and CD142 were elevated 2.5, 6.0-, and 5.0-fold at admission (p<0.001 for all, compared to controls; aspirin only), decreased significantly 24 hours later following initiation of treatment with clopidogrel and subcutaneous anticoagulation (p<0.001 for all), and decreased even further six months later (p<0.01 for all). However, PS⁺PMPs exposing CD62P or CD142 were still between 1.2-and 2.3-fold higher than in controls (p<0.001 for both). The pattern for PS⁻PMPs during and after the ACS was very similar to that for PS⁺PMPs although the numbers were approximately 1/3 lower. In conclusion, PMP concentrations follow the pattern of platelet activation during and after an ACS. Decreased concentrations are observed after initiation of antithrombotic treatment, but PMP exposing CD62P or CD142 are still elevated after six months. Flow cytometric measurements of PMP in frozen-thawed samples enable studies of platelet function in larger clinical trials.

Keywords

Microparticles - tissue factor - P-selectin - phosphatidylserine - ischaemic heart disease

• References

• 1 Breet NJ, van Werkum JW, Bouman HJ. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
• 2 Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl. 01) S13-S33.
• 3 VanWijk MJ, VanBavel E, Sturk A. et al. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59: 277-287.
• 4 Burnier L, Fontana P, Kwak BR. et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
• 5 Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A 2007; 71: 38-45.
• 6 van der Zee PM, Biró E, Ko Y. et al. P-selectin- and CD63-exposing platelet micro-particles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006; 52: 657-664.
• 7 Hou J, Fu Y, Zhou J. et al. Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets. Vox Sang 2011; 100: 187-195.
• 8 Sinauridze EI, Kireev DA, Popenko NY. et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
• 9 Connor DE, Exner T, Ma DF. et al. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 2010; 103: 1044-1052.
• 10 Morel O, Hugel B, Jesel L. et al. Sustained elevated amounts of circulating pro-coagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004; 91: 345-353.
• 11 Morel O, Hugel B, Jesel L. et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 1118-1126.
• 12 Skeppholm M, Kallner K, Malmqvist K. et al. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?. Thromb Res 2011; 128: 483-489.
• 13 Mobarrez F, Antovic J, Egberg N. et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res 2010; 125: e110-116.
• 14 Mobarrez F, Egberg N, Bröijersen A. et al. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res 2012; 129: 95-97.
• 15 Mobarrez F, He S, Bröijersen A. et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived micro-particles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352.
• 16 Gawaz M, Neumann FJ, Ott I. et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
• 17 Flaumenhaft R, Dilks JR, Richardson J. et al. Megakaryocyte-derived micropar-ticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113: 1112-1121.
• 18 Owens III AP, Mackman N. Microparticles in Hemostasis and Thrombosis. Circ Res 2011; 108: 1284-1297.
• 19 Rauch U, Bonderman D, Bohrmann B. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175.
• 20 Schwertz H, Tolley ND, Foulks JM. et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006; 203: 2433-2440.
• 21 Steppich BA, Braun SL, Stein A. et al. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J 2009; 7: 11.
• 22 Serebruany VL, Malinin AI, Jerome SD. et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003; 146: 713-720.
• 23 Nomura S, Takahashi N, Inami N. et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 2004; 174: 329-335.
• 24 Rank A, Nieuwland R, Crispin A. et al. Clearance of platelet microparticles in vivo. Platelets 2011; 22: 111-116.
• 25 Bulut D, Becker V, Mügge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can. J. Physiol. Pharmacol 2011; 89: 239-244.
• 26 Trip MD, Cats VM, van Capelle FJ. et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
• 27 Mallat Z, Steg G, Hugel B. et al. Prognostic value of circulating shed membrane pro-coagulant microparticles in patients with severe acute coronary syndromes. A substudy from the global registry of acute coronary events (GRACE). Circulation. 2004; 110 Suppl S 575. Abstract
• 28 Morel O, Toti F, Hugel B. et al. Procoagulant microparticles: Disrupting the vascular homeostasis equation?. Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
• 29 Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011; 105: 396-408.